[
    [
        {
            "time": "2023-11-07",
            "original_text": "Novartis' Neuroendocrine Tumors Targeted Radiotherapy Takes Small Hit on Clinically Relevant Overall Survival",
            "features": {
                "keywords": [
                    "Neuroendocrine",
                    "Tumors",
                    "Targeted",
                    "Radiotherapy",
                    "Clinically",
                    "Relevant",
                    "Overall",
                    "Survival"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-11-07",
            "original_text": "Novartis (NVS) Announces Data on Radioligand Therapy at ASCO",
            "features": {
                "keywords": [
                    "Novartis",
                    "Radioligand",
                    "Therapy",
                    "ASCO"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-07",
            "original_text": "Novartis announces TabrectaÂ® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC",
            "features": {
                "keywords": [
                    "Tabrecta",
                    "overall",
                    "survival",
                    "response",
                    "METex14",
                    "NSCLC"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-11-07",
            "original_text": "Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy",
            "features": {
                "keywords": [
                    "checkpoint",
                    "inhibitor",
                    "tislelizumab",
                    "primary",
                    "endpoint",
                    "overall",
                    "survival",
                    "Phase",
                    "III",
                    "esophageal",
                    "cancer"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-07",
            "original_text": "Mesoblast (MESO) Q3 2021 Earnings Call Transcript",
            "features": {
                "keywords": [
                    "Mesoblast",
                    "Q3",
                    "Earnings",
                    "Call",
                    "Transcript"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 4,
                "Source_Recency": 4
            }
        }
    ]
]